The H1 picture: Biotech’s vital signs show some life — with one big exception
This past six months, the numbers have started to track upward in biotech — and we’re not just talking about M&A here.
We’re starting to see real evidence that VCs — at least the core group that helped usher in the Covid boom — are not just supporting the hardiest survivors. We’re seeing a definite uptick in launch rounds while Big Pharma continues to put its money where the best human data are.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.